

# Metaproteomics, the path to rapid microbiota diagnosis Jean Armengaud

### ► To cite this version:

Jean Armengaud. Metaproteomics, the path to rapid microbiota diagnosis. XIII Reunion científica sobre proteomica clínica, Fernando Corrales - CSIC / SEProt / Clinica Universidad de Navarra, Nov 2023, Madrid, Spain. hal-04469795

## HAL Id: hal-04469795 https://hal.inrae.fr/hal-04469795

Submitted on 21 Feb 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

#### XIII Reunion cientifica sobre proteomica clínica

#### Madrid 6-7 nov 2023

#### Metaproteomics, the path to rapid microbiota diagnosis

#### Jean ARMENGAUD

Laboratory «Innovative technologies for Detection and Diagnostics», ProGénoMix IBISA platform CEA, Bagnols-sur-Cèze, France

Short abstract:

The microbiota plays a major role in human health. To understand how microbial communities function, how they interact with the host and how dysbiosis can occur, we need to identify the diversity of microorganisms present and quantify the numerous molecular players at work. Proteins are the workhorses of biological systems. Metaproteomics is a key technology for such functional studies, as it can provide five types of answers for these highly complex samples: 1) identification of the taxa present, 2) quantification of the biomass of these organisms, 3) identification of the proteins of these taxa and their function, 4) identification of human biomarkers explaining the host response, and 5) overall functional representation of the biological system. Challenges in terms of mass spectrometry, interpretation and exploitation of results will be addressed using examples of fecal material from COVID19 patients and sputum from cystic fibrosis patients. Recent technologies such as the Astral tandem mass spectrometer will be presented to demonstrate the power of this approach for rapid medical diagnosis.